This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
CENSER was a randomized, parallel-design, quadruple-masked clinical trial evaluating early norepinephrine in patients with septic shock and severe sepsis.
| Feature | CENSER |
|---|---|
| Condition | Septic Shock; Severe Sepsis |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Quadruple |
| Primary purpose | Treatment |
| Lead sponsor | Mahidol University |
2. Clinical Question
Population
Patients with septic shock and severe sepsis.
Intervention
Early norepinephrine.
Comparator
Placebo.
Primary question
Does early norepinephrine improve achievement of the therapeutic goal within 6 hours?
3. Trial Design
310 patients
or placebo
Early norepinephrine
Drug intervention arm.
Placebo
Placebo comparator arm.
4. Endpoints
| Endpoint | Time frame | Definition |
|---|---|---|
| Therapeutic goal achievement | 6 hours | Mean arterial blood pressure ≥ 65 mmHg and evidence of adequate tissue perfusion including urine output ≥ 0.5 ml/kg/hour for 2 hours or decreasing serum lactate ≥ 10 percent in 1 to 2 hours. |
5. Planned Analysis
The registry identifies therapeutic goal achievement at 6 hours as the primary endpoint. This endpoint is a binary clinical outcome: whether the prespecified therapeutic goal is achieved within the assessment period.
A typical analysis for this type of endpoint would compare the proportion of patients achieving the goal in each randomized group using methods for binary outcomes, such as a risk difference, risk ratio, odds ratio, or hypothesis test comparing proportions. The registry does not report posted results or formal statistical analyses for this endpoint.
6. Statistical Methodology
Randomization
Randomization creates treatment groups intended to be comparable at baseline. The treatment comparison should preserve the randomized allocation when estimating efficacy effects.
Binary endpoint analysis
For a therapeutic goal achieved/not achieved endpoint, the absolute difference in proportions directly describes the difference in observed achievement rates between groups.
Masking
The quadruple-masked design reduces the potential influence of expectations from participants, clinicians, investigators, and outcome assessors.
7. Statistical Methods Explained
Why use a randomized design?
Randomization helps separate treatment effects from differences between patient groups by allocating treatment assignment using chance.
Why is the primary endpoint measured at 6 hours?
The registry defines the therapeutic goal assessment at 6 hours, creating a prespecified time point for comparing early resuscitation response.
Why is a binary endpoint different from survival analysis?
A binary endpoint asks whether an event occurred by a specified time. Survival methods are used when the timing of events throughout follow-up is the main focus.
Why does masking matter?
Masking can reduce bias in treatment administration, clinical decisions, and assessment of outcomes.
What does a treatment proportion difference show?
A difference in proportions describes the absolute change in the probability of achieving the endpoint between randomized groups.
8. Limitations
- Registry reporting: The ClinicalTrials.gov record does not report posted statistical analyses or outcome estimates.
- Endpoint interpretation: Therapeutic goal achievement summarizes an early clinical state and does not by itself describe longer-term outcomes.
- Generalizability: Applicability depends on the enrolled septic shock and severe sepsis population represented in the trial.
9. Why This Trial Matters Statistically
| Concept | How it appears in CENSER |
|---|---|
| Randomization | Two-arm randomized comparison. |
| Masking | Quadruple-masked design. |
| Binary outcomes | Therapeutic goal achievement measured at 6 hours. |
| Clinical endpoints | Composite physiologic criteria define response. |
10. Sources
- ClinicalTrials.gov: NCT01945983